EU/3/09/616

Table of contents

About

On 27 February 2009, orphan designation (EU/3/09/616) was granted by the European Commission to Knopp Neurosciences Sub Ltd, United Kingdom, for (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate for the treatment of amyotrophic lateral sclerosis.

The sponsorship was transferred to Biogen Idec Limited, United Kingdom, in March 2011.

Key facts

Active substance
(6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate
Disease / condition
Treatment of amyotrophic lateral sclerosis
Date of decision
27/02/2009
Outcome
Positive
Orphan decision number
EU/3/09/616

Sponsor's contact details

Biogen Idec Limited
Innovation House
70 Norden Road
Maidenhead
Berkshire SL6 4AY
United Kingdom
Tel. +44 (0)1628 501 000
Fax +44 (0)1628 501 010
E-mail: ukreception@biogenidec.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating